Insilico Medicine, which claims to be “a generative artificial intelligence (AI)-driven clinical-stage drug discovery company,” said that it is “the first AI drug discovery company to venture into nebulized formulations” as the company plans to file an IND for its ISM001-055 inhalation solution for the treatment of idiopathic pulmonary fibrosis.
According to the company, ISM001-055 is a small molecule anti-fibrotic, and an oral formulation of the drug is currently in Phase 2 development for IPF. Insilico says that preclinical studies of the inhaled formulation have generated encouraging PK, efficacy, and safety data.
Insilico CEO Alex Zhavoronkov commented, “I am thrilled to see the announcement of inhalation solution for ISM001-055, which is a remarkable milestone for a novel drug candidate, as 99% of programs fail at the preclinical stage. With the support of Pharma.AI driven by generative artificial intelligence, we are making drug discovery more efficient and more accurate, which is proved by the three programs in the clinical stage.”
Read the Insilico Medicine press release.
